Dozens of affiliated scientists are conducting genomics research—basic and applied—that will provide breakthroughs in personalized medicine and better health.
The UB startup will use the $1.5M in Phase II STTR funding to advance technology to test how new drugs affect the heart’s electrical activity.
A UB-led research team will develop tools that simplify analysis of glycans, biomolecules more diverse than the genome.
Findings from the UB “mini-brain” research indicate the disease — triggered by malformations in the cerebral cortex —could potentially be treated in utero.
The region, where humans leaving Africa may have first met Neanderthals, holds a unique spot in human evolution, UB scientists say.
Elevated bile acids in patients with non-alcoholic fatty liver disease point to novel interventions, such as personalized probiotics.
Members of the Communities of Excellence gathered to review the impact they have had on education, scholarship and outreach.
The funded projects are focused on improving our understanding of the human genome and microbiome.
Putting surgeons and researchers in the same facility is leading to world-class innovations.